

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**

**加科思藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1167)**

**VOLUNTARY ANNOUNCEMENT**

**JACOBIO RECEIVED \$100 MILLION UPFRONT PAYMENT FROM  
ASTRAZENECA UNDER THE LICENSE AND COOPERATION AGREEMENT  
FOR THE PAN-KRAS INHIBITOR JAB-23E73.**

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

Reference is made to the announcement of the Company dated December 21, 2025 in relation to the entering into the licence and collaboration agreement (the “**Licence and Collaboration Agreement**”) by Jacobio Pharmaceuticals Co., Ltd. (北京加科思新藥研發有限公司) (“**Beijing Jacobio**”) and AstraZeneca AB (“**AstraZeneca**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as defined in the Announcement.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Beijing Jacobio, an indirect non-wholly owned subsidiary of the Company has received the upfront payment of US\$100.0 million from AstraZeneca pursuant to the Licence and Collaboration Agreement. The receipt of such upfront payment will further bolster the Group’s cash reserves and facilitate the advancement of the Group’s subsequent pipeline development of innovative oncology therapies.

## **About Jacobio**

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around targeted oncology and tumor immunotherapy with pipelines in KRAS, Sting, P53 and MYC pathways. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

By Order of the Board  
**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**  
**Yinxiang WANG**  
*Chairman*

Hong Kong, March 30, 2026

*As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.*